Hemodynamic aspects of the treatment of ischemic heart disease.
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D001794:Blood Pressure / Q000187:drug effects; D002118:Calcium / Q000037:antagonists & inhibitors; D002302:Cardiac Output / Q000187:drug effects; D003327:Coronary Disease / Q000503:physiopathology / Q000628:therapy*; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008013:Lidoflazine / Q000494:pharmacology; D009200:Myocardial Contraction / Q000187:drug effects; D009206:Myocardium / Q000378:metabolism; D009574:Nitro Compounds / Q000494:pharmacology; D005996:Nitroglycerin / Q000494:pharmacology; D010101:Oxygen Consumption / Q000187:drug effects; D014655:Vascular Resistance / Q000187:drug effects; D014665:Vasodilator Agents / Q000494:pharmacology
D000319:Adrenergic beta-Antagonists; D009574:Nitro Compounds; D014665:Vasodilator Agents; D005996:Nitroglycerin; D008013:Lidoflazine; D002118:Calcium